European Medicines Agency Recommends Withdrawal Of The Marketing Authorisations For Lumiracoxib-Containing Medicines. Medical News TODAY. Dec 14. 2007.The European Medicines Agency (EMEA) has recommended the withdrawal of the marketing authorisations for all lumiracoxib-containing medicines, because of the risk of serious side effects affecting the liver. Lumiracoxib is a non-steroidal anti-inflammatory drug (NSAID) that belongs to the group ‘COX-2 inhibitors’. It is used for symptomatic relief in the treatment of osteoarthritis of the hip and knee. [ See ]. Image from article in Spanish.